Supernus Pharmaceuticals seeks FDA approval for ADHD drug

//Supernus Pharmaceuticals seeks FDA approval for ADHD drug

Supernus Pharmaceuticals seeks FDA approval for ADHD drug

The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. If granted, that could mean getting the treatment to patients in the second half of 2020. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2019-11-12T23:14:41+00:00 November 12th, 2019|Healthcare|

About the Author: